Repayment Provisions. If the Company is required to prepare an accounting restatement due to its material noncompliance, as a result of the Executive’s misconduct, with any financial reporting requirement under United States securities laws, then, and only if Section 304 of the ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act of 2002, or a successor provision, is then in effect, the Company may require the Executive to reimburse the Employer for (i) any bonus or other incentive-based or equity-based compensation received by the Executive from the Employer during the 12-month period following the first public issuance or filing with the Securities Exchange Commission (whichever first occurs) of the financial documents embodying such financial reporting requirement and (ii) any profits realized from the sale of securities of Company during such 12-month period.
Appears in 6 contracts
Sources: Employment Agreement (Achieve Life Sciences, Inc.), Employment Agreement (Achieve Life Sciences, Inc.), Employment Agreement (Achieve Life Sciences, Inc.)
Repayment Provisions. If the Company is required to prepare an accounting restatement due to its material noncompliance, as a result of the Executive’s misconduct, with any financial reporting requirement under United States securities laws, then, and only if Section 304 of the ▇S▇▇▇▇▇▇▇-▇▇▇▇▇ Act of 2002, or a successor provision, is then in effect, the Company may require the Executive to reimburse the Employer Company for (i) any bonus or other incentive-based or equity-based compensation received by the Executive from the Employer Company during the 12-month period following the first public issuance or filing with the Securities Exchange Commission (whichever first occurs) of the financial documents embodying such financial reporting requirement and (ii) any profits realized from the sale of securities of Company during such 12-month period.
Appears in 5 contracts
Sources: Employment Agreement (Trubion Pharmaceuticals, Inc), Employment Agreement (Trubion Pharmaceuticals, Inc), Employment Agreement (Trubion Pharmaceuticals, Inc)
Repayment Provisions. If the Company is required to prepare an accounting restatement due to its material noncompliance, as a result of the Executive’s misconduct, with any financial reporting requirement under United States securities laws, then, and only if Section 304 of the ▇S▇▇▇▇▇▇▇-▇▇▇▇▇ Act of 2002, or a successor provision, is then in effect, the Company may require the Executive to reimburse the Employer for (i) any bonus or other incentive-based or equity-based compensation received by the Executive from the Employer during the 12-month period following the first public issuance or filing with the Securities Exchange Commission (whichever first occurs) of the financial documents embodying such financial reporting requirement and (ii) any profits realized from the sale of securities of Company during such 12-month period.
Appears in 3 contracts
Sources: Employment Agreement (Achieve Life Sciences, Inc.), Employment Agreement (Achieve Life Sciences, Inc.), Employment Agreement (Oncogenex Pharmaceuticals, Inc.)
Repayment Provisions. If the Company is required to prepare an accounting restatement due to its material noncompliance, noncompliance as a result of the Executive’s misconduct, misconduct with any financial reporting requirement under United States securities laws, then, and only if Section 304 of the ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act of 2002, or 2002,or a successor provision, is then in effect, the Company may require the Executive to reimburse the Employer for (i) any bonus or other incentive-based or equity-based compensation received by the Executive from the Employer during the 12-month period following the first public issuance or filing with the Securities Exchange Commission (whichever first occurs) of the financial documents embodying such financial reporting requirement and (ii) any profits realized from the sale of securities of Company during such 12-month period.
Appears in 3 contracts
Sources: Transition and Separation Agreement, Terms of Transition and Separation (Oncogenex Pharmaceuticals, Inc.), Employment Agreement (Oncogenex Pharmaceuticals, Inc.)
Repayment Provisions. If the Company is required to prepare an accounting restatement due to its material noncompliance, as a result of the ExecutiveEmployee’s misconduct, with any financial reporting requirement under United States securities laws, then, and only if Section 304 of the ▇S▇▇▇▇▇▇▇-▇▇▇▇▇ Act of 2002, or a successor provision, is then in effect, the Company may require the Executive Employee to reimburse the Employer for (i) any bonus or other incentive-based or equity-based compensation received by the Executive Employee from the Employer during the 12-month period following the first public issuance or filing with the Securities Exchange Commission (whichever first occurs) of the financial documents embodying such financial reporting requirement and (ii) any profits realized from the sale of securities of Company during such 12-month period.
Appears in 1 contract